A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Jenny Li
- Telefonnummer: 650-237-9339
- E-post: clinicaltrials@miracogen.com.cn
Studer Kontakt Backup
- Navn: Leanne Drummond, Bachelor
- Telefonnummer: 984-208-9519
- E-post: leanne.drummond@worldwide.com
Studiesteder
-
-
California
-
Orange, California, Forente stater, 92868-3201
- Chao Family Comprehensive Cancer Center
-
-
New York
-
New York, New York, Forente stater, 10065
- Memorial Sloan Kettering 60th Street Outpatient Center
-
-
Ohio
-
Canton, Ohio, Forente stater, 44718
- Gabrail Cancer Center Research
-
Cincinnati, Ohio, Forente stater, 45219
- The Christ Hospital Cancer Center
-
-
Pennsylvania
-
Gettysburg, Pennsylvania, Forente stater, 17325
- Gettysburg Cancer Center
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Virginia Cancer Specialists
-
-
-
-
Hunan
-
Changsha, Hunan, Kina, 410013
- Hunan Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 201321
- Fudan University Shanghai Cancer Center
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310003
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Understands and provides written informed consent and willing to follow the requirements specified in protocol.
- Age ≥18 years.
- Life expectancy ≥6 months.
- For Part B patients, documented Tissue Factor (TF) presence in tumor biopsy specimens obtained from archival or re-biopsy specimens by immunohistochemistry (IHC) protein expression.
- Must have histologically or cytologically confirmed unresectable or metastatic cancer with documented disease progression during prior therapy, or relapse or progression following approved standard therapy for their tumor types- Part A and Part B.
- Part B: Patients who have documented progression during or relapse following standard therapy, no further treatment options that are known to improve survival, and participation in a clinical trial is a reasonable therapeutic option.
- Patients must have measurable disease per RECIST v1.1.
- ECOG performance status of 0 or 1.
- Acceptable bone marrow, hepatic, cardiac, renal, and coagulation function.
- A negative serum pregnancy test if female and aged between 18-55 years old.
- Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for 180 days after the last infusion of MRG004A.
Exclusion Criteria:
- Archival or biopsy tumor shows TF IHC membrane or cytosolic score of zero, no TF-positive expression or no TF-positive staining in Part B patients.
- Toxicities (except alopecia & fatigue) due to prior antitumor therapy are greater than CTCAE v5.0 Grade 1.
- Toxicities due to prior radiotherapy that have not resolved to Grade ≤ 1 CTCAE v5.0 at least 21 days prior to the first treatment.
- Untreated, unstable or uncontrolled central nervous system (CNS) metastases.
- Any other type of anti-cancer therapy within 21 days of the first dose of study treatment. Use of any other type of anti-cancer treatment is prohibited throughout the study.
- Patients with increased bleeding risk.
- Presence of severe cardiac dysfunction.
- Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of study drug.
- Concurrent malignancy within 5 years prior to entry.
- Uncontrolled or poorly controlled hypertension.
- History of ventricular tachycardia, or torsade des pointes.
- History of moderate to severe dyspnea at rest.
- Major surgery within 4 weeks of the first dose of study treatment and not fully recovered. Minor surgery within 2 weeks prior to study treatment.
- Known allergic reactions to any component or excipient of MRG004A or known allergic reactions to other prior anti-TF (including investigational) or other monoclonal antibody ≥ Grade 3.
- Patients who have any known liver disease, including chronic hepatitis B, hepatitis C, autoimmune hepatic disorders, primary biliary cirrhosis or sclerosing cholangitis; Patients who have concurrent, serious, uncontrolled infections or known infection with HIV, or have a diagnosed acquired immunodeficiency syndrome (AIDS); or an uncontrolled autoimmune disease, or have undergone organ transplant.
- Active uncontrolled bacterial, viral, fungal, rickettsial, or parasitic infection.
- Use of systemic corticosteroids within 4 weeks prior to the first dose of treatment.
- Use of strong CYP3A4 inhibitors or inducers with MRG004A.
- Other excluded medications or treatment: therapeutic anti-coagulative, or long-term anti-platelet treatment; multivitamins, calcium, vitamin D, and prophylactic anti-RANKL (denosumab) and zoledronic acid therapies for bone metastases are allowed.
- Any patient with a positive pregnancy or is breast-feeding.
- Any severe and/or uncontrolled systemic disease that at the discretion of investigator and sponsor makes it undesirable for the patient to participate in this study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: MRG004A
All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
|
Administrated intravenously
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Tidsramme: DLT will be evaluated during the first treatment cycle (Day 1-21)
|
The highest dose confirmed wherein less than 2 out of 6, or < 33% of evaluable patients in a treatment cohort experiences dose-limiting toxicity (DLT).
|
DLT will be evaluated during the first treatment cycle (Day 1-21)
|
|
Recommended Phase II Dose (RP2D)
Tidsramme: Baseline to study completion (up to 24 months)
|
The dose level of MRG004A recommended for further clinical studies based on assessment of the safety, efficacy and PK data from Part A of this study.
|
Baseline to study completion (up to 24 months)
|
|
Objective Response Rate (ORR)
Tidsramme: Baseline to study completion (up to 24 months)
|
The proportion of patients who achieve complete response (CR) or partial response (PR) as assessed by the Independent Central Review (ICR).
|
Baseline to study completion (up to 24 months)
|
|
Adverse Events (AEs)
Tidsramme: From signing informed consent until 45 days after the last dose of MRG004A
|
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.
|
From signing informed consent until 45 days after the last dose of MRG004A
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Responsens varighet (DOR)
Tidsramme: Baseline for å studere fullføring (opptil 24 måneder)
|
Tidsintervallet mellom datoen for den tidligste kvalifiserende responsen og datoen for sykdomsprogresjon eller død av enhver årsak, avhengig av hva som skjer tidligere.
|
Baseline for å studere fullføring (opptil 24 måneder)
|
|
Disease Control Rate (DCR)
Tidsramme: Baseline to study completion (up to 24 months)
|
The proportion of patients who achieve CR, PR, or stable disease (SD) ≥ 6 weeks based on RECIST v1.1.
|
Baseline to study completion (up to 24 months)
|
|
Progression Free Survival (PFS)
Tidsramme: Baseline to study completion (up to 24 months)
|
The time from the date of first study dose to disease progression or death whichever occurs first.
|
Baseline to study completion (up to 24 months)
|
|
Overall Survive (OS)
Tidsramme: Baseline to study completion (up to 24 months)
|
The time from start of study treatment to date of death as a result of any cause.
|
Baseline to study completion (up to 24 months)
|
|
Pharmacokinetics (PK) Parameter of MRG004A: Cmax
Tidsramme: Baseline to 30 days after the last dose of study treatment
|
Maximum observed plasma concentration.
|
Baseline to 30 days after the last dose of study treatment
|
|
Pharmacokinetics (PK) Parameter of MRG004A: Tmax
Tidsramme: Baseline to 30 days after the last dose of study treatment
|
Time to reach the maximum plasma concentration.
|
Baseline to 30 days after the last dose of study treatment
|
|
Pharmacokinetics (PK) Parameter of MRG004A: AUClast
Tidsramme: Baseline to 30 days after the last dose of study treatment
|
Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration.
|
Baseline to 30 days after the last dose of study treatment
|
|
Forekomst av antistoff-antistoff (ADA)
Tidsramme: Baseline til 30 dager etter siste dose av studiebehandlingen
|
Andelen pasienter med positiv ADA-immunogenisitet resultater.
|
Baseline til 30 dager etter siste dose av studiebehandlingen
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Nashat Y Gabrail, MD, Gabrail Cancer Center Research
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- MRG004A-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .